JP2024529476A - 新規スピロピロリジン誘導抗ウイルス剤 - Google Patents

新規スピロピロリジン誘導抗ウイルス剤 Download PDF

Info

Publication number
JP2024529476A
JP2024529476A JP2024505183A JP2024505183A JP2024529476A JP 2024529476 A JP2024529476 A JP 2024529476A JP 2024505183 A JP2024505183 A JP 2024505183A JP 2024505183 A JP2024505183 A JP 2024505183A JP 2024529476 A JP2024529476 A JP 2024529476A
Authority
JP
Japan
Prior art keywords
optionally substituted
compound
mmol
alkyl
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529476A5 (cg-RX-API-DMAC10.html
Inventor
シェン、ルイチャオ
ヘ、ヨン
シン、シュエチャオ
ローデス、マシュー、シー．
パナレーゼ、ジョゼフ、ディー．
バートレット、サミュエル
リ、ウェイ
カオ、ホイ
チャン、ジャユン
ペン、シャオウェン
ワン、グオチェン
サン オル、ヤット
Original Assignee
エナンタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/479,248 external-priority patent/US11325916B1/en
Application filed by エナンタ ファーマシューティカルズ インコーポレイテッド filed Critical エナンタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2024529476A publication Critical patent/JP2024529476A/ja
Publication of JP2024529476A5 publication Critical patent/JP2024529476A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024505183A 2021-07-29 2022-04-14 新規スピロピロリジン誘導抗ウイルス剤 Pending JP2024529476A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163227206P 2021-07-29 2021-07-29
US63/227,206 2021-07-29
US17/479,248 2021-09-20
US17/479,248 US11325916B1 (en) 2021-07-29 2021-09-20 Spiropyrrolidine derived antiviral agents
US202263324367P 2022-03-28 2022-03-28
US63/324,367 2022-03-28
PCT/US2022/024772 WO2023009187A1 (en) 2021-07-29 2022-04-14 Novel spiropyrrolidine derived antiviral agents

Publications (2)

Publication Number Publication Date
JP2024529476A true JP2024529476A (ja) 2024-08-06
JP2024529476A5 JP2024529476A5 (cg-RX-API-DMAC10.html) 2025-03-05

Family

ID=85087186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505183A Pending JP2024529476A (ja) 2021-07-29 2022-04-14 新規スピロピロリジン誘導抗ウイルス剤

Country Status (8)

Country Link
EP (1) EP4376834A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024529476A (cg-RX-API-DMAC10.html)
KR (1) KR20240044452A (cg-RX-API-DMAC10.html)
AU (1) AU2022319598A1 (cg-RX-API-DMAC10.html)
CA (1) CA3173702A1 (cg-RX-API-DMAC10.html)
IL (1) IL310246A (cg-RX-API-DMAC10.html)
MX (1) MX2024001377A (cg-RX-API-DMAC10.html)
WO (1) WO2023009187A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7559223B2 (ja) 2020-08-24 2024-10-01 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物及びその使用
TWI925033B (zh) 2020-10-16 2026-05-11 美商基利科學股份有限公司 磷脂化合物及其用途
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds
EP4612156A1 (en) * 2022-11-02 2025-09-10 Aligos Therapeutics, Inc. Anti-viral compounds
CN119139307B (zh) * 2023-12-29 2025-09-23 上海柯君医药科技有限公司 螺环类化合物在制备3CLpro蛋白酶抑制剂或药物中的用途
WO2025221657A1 (en) * 2024-04-15 2025-10-23 Aligos Therapeutics, Inc. Anti-viral compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006061714A2 (en) * 2004-12-09 2006-06-15 Pfizer Inc. Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
JP2010502620A (ja) * 2006-08-30 2010-01-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｄｍ２の小分子阻害剤およびその使用
JP2010519329A (ja) * 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ阻害剤
WO2018042343A2 (en) * 2016-08-30 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Compounds that inhibit 3c and 3cl proteases and methods of use thereof
US20220402926A1 (en) * 2021-05-11 2022-12-22 Enanta Pharmaceuticals, Inc. Novel macrocyclic spiropyrrolidine derived antiviral agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8222288B2 (en) * 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
US11325916B1 (en) * 2021-07-29 2022-05-10 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023086400A1 (en) * 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
WO2023125825A1 (en) * 2021-12-29 2023-07-06 Shanghai Curegene Pharmaceutical Co., Ltd. Anticoronviral compounds and compositions and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006061714A2 (en) * 2004-12-09 2006-06-15 Pfizer Inc. Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
JP2010502620A (ja) * 2006-08-30 2010-01-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｄｍ２の小分子阻害剤およびその使用
JP2010519329A (ja) * 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ阻害剤
WO2018042343A2 (en) * 2016-08-30 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Compounds that inhibit 3c and 3cl proteases and methods of use thereof
US20220402926A1 (en) * 2021-05-11 2022-12-22 Enanta Pharmaceuticals, Inc. Novel macrocyclic spiropyrrolidine derived antiviral agents

Also Published As

Publication number Publication date
KR20240044452A (ko) 2024-04-04
EP4376834A4 (en) 2025-06-18
WO2023009187A1 (en) 2023-02-02
AU2022319598A1 (en) 2024-02-08
EP4376834A1 (en) 2024-06-05
CA3173702A1 (en) 2023-01-29
IL310246A (en) 2024-03-01
MX2024001377A (es) 2024-03-08

Similar Documents

Publication Publication Date Title
JP7795521B2 (ja) 抗ウイルス剤としての官能化ペプチド
US12479854B2 (en) Spiropyrrolidine derived antiviral agents
AU2021381437B2 (en) Novel spiropyrrolidine derived antiviral agents
US12540141B2 (en) Spiropyrrolidine derived antiviral agents
US11325916B1 (en) Spiropyrrolidine derived antiviral agents
US12145942B2 (en) Spiropyrrolidine derived antiviral agents
WO2022036018A1 (en) Functionalized peptides as antiviral agents
JP2024500286A (ja) 新規スピロピロリジン誘導抗ウイルス剤
US20230115107A1 (en) Novel spiropyrrolidine derived antiviral agents
WO2023086350A1 (en) Alkyne-containing antiviral agents
WO2023009187A1 (en) Novel spiropyrrolidine derived antiviral agents
WO2023086352A1 (en) Novel spiropyrrolidine derived antiviral agents
US12145941B2 (en) Heterocyclic antiviral agents
WO2023003610A1 (en) Novel spiropyrrolidine derived antiviral agents
CN118043045A (zh) 新型螺吡咯烷衍生的抗病毒药物
EA050743B1 (ru) Новые противовирусные агенты на основе производных спиропирролидина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260707

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260730